Idorsia Ltd (CH:IDIA)
:IDIA
Want to see CH:IDIA full AI Analyst Report?
Top Page
Idorsia Ltd
(IDIA)
Select Model
Select Model
Rating:50Neutral
Price Target:
CHF4.00
▲(7.82% Upside)
Action:Reiterated
Date:05/28/26
The score is held down primarily by weak financial performance—persistent losses, ongoing cash burn, and a highly stressed balance sheet with negative equity and heavy debt. Technicals are relatively supportive with the stock trading above major moving averages and moderate positive momentum, while valuation remains constrained due to negative earnings and no dividend yield provided.
Positive Factors
High gross margins
Sustained ~90% gross margins indicate durable product-level economics and strong pricing or low COGS for marketed assets. Over 2-6 months this supports resilience to sales volatility and gives room to absorb SG&A, licensing or R&D investment if commercial traction improves.
Negative Factors
Highly stressed balance sheet
Deeply negative equity and debt far exceeding assets materially constrain financial flexibility, raising refinancing and covenant risk. Over the medium term this limits the company's ability to fund development or commercial expansion without dilutive equity or onerous financing.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained ~90% gross margins indicate durable product-level economics and strong pricing or low COGS for marketed assets. Over 2-6 months this supports resilience to sales volatility and gives room to absorb SG&A, licensing or R&D investment if commercial traction improves.
Read all positive factors
Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.15B
Dividend YieldN/A
Average Volume (3M)2.48M
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth96.06%
EPS Growth69.34%
CountryCH
Employees636
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.95
Shares Outstanding255,040,510
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside28.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.56
Revenue Forecast (FY)CHF227.22M
Idorsia Ltd Business Overview & Revenue Model
Company Description
Idorsia Ltd is a biopharmaceutical company based in Switzerland, dedicated to the discovery, development, and commercialization of innovative medicines that address significant unmet medical needs. The company maintains a diverse clinical developm...
How the Company Makes Money
Idorsia makes money primarily through (1) net product sales of its approved medicine QUVIVIQ (daridorexant), where revenue is recognized from selling the product into distribution channels (e.g., wholesalers/distributors) in markets where it is co...
Idorsia Ltd Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call communicated a clear operational turnaround: materially stronger commercial traction (QUVIVIQ sales > doubled, EUCAN strength), significant cost savings, improved operating losses and strengthened liquidity. These positives are balanced by remaining profitability gaps, U.S. access/regulatory uncertainty for QUVIVIQ (descheduling pending), an unfinished TRYVIO commercialization partnership process, and multi‑year timelines for key pipeline readouts (e.g., lucerastat). On balance, the company presented meaningful progress and a credible path to further de‑risking and growth, while acknowledging key near‑term risks tied to partnerships, U.S. regulatory outcomes and cash runway beyond the next inflection points.Positive Updates
QUVIVIQ Sales More Than Doubled
QUVIVIQ product sales increased from ~CHF 60–61 million in 2024 to CHF 134 million in 2025 (≈+123%), driving net revenue to CHF 214 million and exceeding the upgraded 2025 guidance (guided CHF 130 million). Company guides QUVIVIQ sales of ~CHF 200 million for 2026 (≈+49% vs 2025).
Negative Updates
Still Operating at a Loss
Despite substantial improvement, company remains unprofitable: non‑GAAP operating loss of CHF -100 million and U.S. GAAP net loss of CHF -112 million in 2025. Financial expenses were CHF 72 million, including a CHF 61 million noncash expense tied to convertible bond restructuring.
Read all updates
Q4-2025 Updates
Positive
Negative
QUVIVIQ Sales More Than Doubled
QUVIVIQ product sales increased from ~CHF 60–61 million in 2024 to CHF 134 million in 2025 (≈+123%), driving net revenue to CHF 214 million and exceeding the upgraded 2025 guidance (guided CHF 130 million). Company guides QUVIVIQ sales of ~CHF 200 million for 2026 (≈+49% vs 2025).
Read all positive updates
Company Guidance
Idorsia guided QUVIVIQ sales of around CHF 200 million for 2026 (up from CHF 134M in 2025, which exceeded the prior guidance of CHF 130M) and said 2026 OpEx (including COGS) will be flat versus 2025, a combination it expects to produce the company’s first positive commercial contribution and drive overall losses lower toward profitability and cash‑flow breakeven. For 2025 the company reported net revenue of CHF 214M (including CHF 134M QUVIVIQ product sales), non‑GAAP contract revenue CHF 72M, a non‑GAAP operating loss improved to CHF ‑100M (from CHF ‑308M in 2024), U.S. GAAP EBIT loss CHF ‑33M and U.S. GAAP net loss CHF ‑112M; cost rationalization saved >CHF 80M and a Viatris negotiation (USD 100M reduction in cost‑sharing) produced a CHF 90M gain. Liquidity at year‑end was CHF 89M with access to a further CHF 80M (total CHF 169M) after drawing CHF 70M of a CHF 150M facility and raising CHF 68M net from equity, and management said it will limit guidance to the one‑year horizon given multiple upcoming inflection points (descheduling, partnerships and pipeline readouts).Idorsia Ltd Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 219.12M | 221.00M | 112.51M | 152.39M | 97.10M | 35.35M |
| Gross Profit | 192.56M | 182.23M | -67.08M | 145.24M | 90.84M | 17.32M |
| EBITDA | -143.64M | -45.49M | -319.49M | -254.55M | -783.09M | -588.84M |
| Net Income | -220.75M | -112.00M | -263.76M | -297.92M | -827.90M | -634.60M |
Balance Sheet | ||||||
| Total Assets | 480.46M | 465.88M | 505.89M | 500.00M | 904.18M | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 94.70M | 87.24M | 124.36M | 157.82M | 476.32M | 1.04B |
| Total Debt | 1.32B | 1.27B | 1.26B | 1.20B | 1.23B | 1.16B |
| Total Liabilities | 1.66B | 1.60B | 1.72B | 1.47B | 1.57B | 1.38B |
| Stockholders Equity | -1.18B | -1.14B | -1.21B | -968.72M | -660.96M | 104.20M |
Cash Flow | ||||||
| Free Cash Flow | -140.32M | -167.05M | -373.23M | -638.69M | -886.17M | -620.83M |
| Operating Cash Flow | -125.95M | -153.23M | -370.23M | -629.30M | -859.11M | -589.89M |
| Investing Cash Flow | -4.32M | 4.16M | 305.06M | 632.61M | 743.90M | -53.26M |
| Financing Cash Flow | 174.98M | 132.14M | 26.11M | -197.00K | 162.31M | 604.15M |
Idorsia Ltd Technical Analysis
Positive
3.71
Price Trends
3.96
Positive
3.79
Positive
3.70
Positive
Market Momentum
0.14
Positive
58.43
Neutral
68.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Positive. The current price of 3.71 is below the 20-day moving average (MA) of 4.31, below the 50-day MA of 3.96, and above the 200-day MA of 3.70, indicating a bullish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 68.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:IDIA.
Idorsia Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF612.52M | 18.84 | ― | ― | 11.43% | -48.80% | |
56 Neutral | CHF808.51M | 490.31 | -7.82% | ― | 59.85% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | CHF1.15B | -5.19 | ― | ― | 96.06% | 69.34% | |
50 Neutral | CHF250.92M | -19.68 | ― | ― | -63.05% | -187.61% | |
44 Neutral | CHF231.02M | -4.24 | -301.13% | ― | 97.32% | -11.07% | |
43 Neutral | CHF122.34M | -1.96 | -51.05% | ― | -100.00% | 9.23% |
* General Sector Average
CH:IDIA
Idorsia Ltd
4.54
2.37
109.52%
CH:MOLN
Molecular Partners AG
3.03
-0.04
-1.30%
CH:BSLN
Basilea Pharmaceutica
49.85
-1.65
-3.20%
CH:KURN
Kuros Biosciences
20.50
-6.22
-23.28%
CH:NWRN
Newron Pharmaceuticals SpA
12.06
4.86
67.50%
CH:SANN
Santhera Pharmaceuticals Holding
15.60
3.56
29.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.